ATEC (ATEC) Q1 2023: Surgical Revenue Up 55% as Robotics and Informatics Drive Adoption
ATEC’s Q1 marked a pivotal acceleration in procedural innovation, with robotics and informatics integration fueling surgeon adoption and margin leverage. The company’s distinct approach to lateral spine surgery and the expansion of its Alpha Informatics platform are reshaping its competitive positioning. Forward guidance points to continued volume-driven growth, with international ramp and robotics integration poised to unlock further upside.
Summary
- Procedural Expansion: ATEC’s lateral and informatics platforms are accelerating surgeon adoption and product utilization.
- Margin Leverage Unlocked: Operational scale is translating into significant EBITDA margin improvement as complexity and product mix shift upward.
- Robotics Integration Watch: Fusion Robotics and navigation assets are set to become revenue contributors and procedural differentiators by 2025.
Business Overview
ATEC (Alphatec Holdings) designs, develops, and markets innovative solutions for spine surgery, with a focus on procedural sophistication and clinical distinction. The company generates revenue through two main segments: Surgical (spine implants, procedural systems, and biologics) and EOS (information-driven imaging and informatics). Its core business model relies on driving surgeon adoption of differentiated procedural platforms, expanding product utilization per case, and leveraging advanced technologies such as robotics and informatics to enhance outcomes and efficiency.
Performance Analysis
ATEC delivered a standout Q1, with total revenue of $109 million driven by 55% growth in surgical revenue and a 46% increase in EOS revenue. The company’s outperformance is rooted in a 40% jump in procedural volume and an 11% rise in revenue per case, reflecting a shift to higher-complexity procedures and greater product attachment. Margin dynamics improved meaningfully, with adjusted EBITDA margin up by over 1,000 basis points year-over-year, as SG&A leverage and infrastructure efficiency took hold.
The company’s lateral procedural platforms, notably PTP (Prone Transpsoas) and the newly launched LTP (Lateral Transpsoas), were the primary growth engines, while posterior expandable cages and biologics also contributed solidly. EOS revenue, now $15 million for the quarter, is beginning to reflect traction in both domestic and select international markets. R&D investment remains elevated, at 11% of sales, as ATEC accelerates the build-out of its Alpha Informatics and robotics capabilities.
- Procedural Complexity Drives Revenue: Product mix shift toward high-complexity, multi-product cases is expanding revenue per surgery and deepening surgeon engagement.
- SG&A Leverage Materializes: Operating expense as a percent of sales fell sharply, unlocking over 1,200 basis points of operating leverage year-over-year.
- Cash Burn Moderates: While Q1 cash use was $35 million, management expects full-year cash burn to improve as EBITDA approaches breakeven.
ATEC’s top-line acceleration is translating into both operational leverage and increased confidence in achieving its long-range profitability goals.
Executive Commentary
"The momentum for the company is exceedingly strong... extended momentum of PTP was the strongest contributor to Q1 growth. Fully launched LTP... introduced Invictus direct vertebral rotation, AIS system... acquired the navigation-enabled robotics platform to enhance precision of our procedural strategy."
Pat Miles, Chairman and CEO
"We delivered over 1,100 basis points of improvement... as sales growth drives leverage across our business, we continue to expect to achieve adjusted EBITDA breakeven for the full year 2023."
Todd Koenig, CFO
Strategic Positioning
1. Procedural Innovation as a Growth Engine
ATEC’s core strategy is to “proceduralize” spine surgery—designing new surgical approaches (like PTP and LTP) that integrate proprietary tools, imaging, and informatics. This procedural distinctiveness compels surgeon adoption and increases product density per case, driving both volume and revenue per procedure.
2. Informatics and Robotics Integration
The Alpha Informatics platform, EOS imaging, and SafeOp neuromonitoring form an information ecosystem that automates planning, intraoperative guidance, and postoperative assessment. The recent acquisition of Fusion Robotics enables ATEC to offer navigation-enabled, EMG-verified screw placement and real-time neural monitoring, aiming to set a new standard for surgical precision and safety.
3. Commercial Execution and Surgeon Training
Surgeon education is a leading indicator of adoption: ATEC hosted 100 surgeon trainings in Q1 and expects 400–500 for the year. The company’s field force expansion and targeted geographic fill-in are deepening penetration and driving cohort utilization up each year.
4. International Expansion
Australia and New Zealand are now live, with Japan targeted for 2025. Early traction in Australia reflects strong local adoption of lateral surgery and a robust team foundation. International revenue is expected to be modest in 2023 but should ramp in the coming years as regulatory and commercial groundwork matures.
5. Portfolio Synergy and Variable Mitigation
ATEC’s thesis is that spine surgery is not commoditized; instead, outcomes depend on variable mitigation through information and precision. The integration of imaging, navigation, robotics, and neurophysiology is designed to reduce revision rates and improve predictability, setting ATEC apart from peers focused on hardware alone.
Key Considerations
ATEC’s Q1 results highlight a business at an inflection point, with procedural innovation and technology integration driving both growth and operating leverage. The company’s ability to scale its commercial engine, integrate robotics, and expand internationally will be key to sustaining momentum.
Key Considerations:
- Product Mix Evolution: Higher-value procedures and increased biologics attachment rates are expanding average revenue per case.
- Technology Platform Leverage: Fusion Robotics and Alpha Informatics are positioned to become integrated procedural standards, not just add-ons.
- Surgeon Adoption Flywheel: Training investments are compounding, with experienced users growing at 48% and driving utilization up the complexity curve.
- International Ramp: Australia is contributing in 2023, Japan expected in 2025, providing optionality for future growth beyond the U.S. market.
- Margin Pathway: SG&A leverage and mix shift are unlocking EBITDA improvement, with breakeven targeted for full-year 2023.
Risks
Integration risk is elevated as ATEC brings together robotics, informatics, and procedural platforms. Delays in regulatory clearance, surgeon adoption curves, or international market entry could slow momentum. Competitive pressure from larger incumbents and ongoing industry consolidation could intensify, especially if rivals accelerate their own technology integration or undercut on price. Cash burn, while moderating, remains a watchpoint until sustained free cash flow is achieved.
Forward Outlook
For Q2 and full-year 2023, ATEC guided to:
- Full-year revenue of approximately $450 million (28% YoY growth)
- Surgical revenue of $393 million, EOS revenue of $57 million
- Adjusted EBITDA breakeven for the full year, with 800 basis points of margin expansion targeted
Management highlighted:
- High teens percent procedure volume growth, up from prior mid-teens forecast
- High single-digit average revenue per surgery growth, driven by mix shift and procedural complexity
Takeaways
ATEC is executing on a differentiated procedural and technology-driven strategy that is translating into robust growth, margin leverage, and expanding adoption.
- Procedural Distinction Drives Adoption: Integrated platforms like PTP, LTP, EOS, and SafeOp are compelling surgeons to increase utilization and complexity.
- Margin Expansion Validates Model: SG&A and operating leverage are materializing as scale builds, supporting a credible path to profitability.
- Technology Integration and International Optionality: Fusion Robotics and Alpha Informatics are set to become future growth levers, with international markets providing further upside.
Conclusion
ATEC’s Q1 demonstrates that its procedural innovation and technology integration strategy is gaining real-world traction with surgeons and translating into both growth and operating leverage. The company’s ability to scale its commercial model, integrate robotics, and expand globally will determine whether it can sustain this trajectory and set a new standard in spine surgery.
Industry Read-Through
ATEC’s results signal that procedural integration and informatics are becoming key battlegrounds in the spine surgery industry. The move toward comprehensive, information-driven platforms—combining imaging, robotics, and real-time neurophysiology—raises the bar for both outcomes and surgeon experience. Competitors focused solely on hardware risk losing share as the market rewards platforms that deliver variable mitigation and procedural predictability. The rapid adoption of lateral procedures and the international ramp also highlight the global appetite for advanced spine solutions, suggesting that innovation and commercial agility will separate winners from laggards in the next cycle.